{"id":"https://openalex.org/W1978379264","doi":"https://doi.org/10.1007/s002280050673","title":"Drug-drug interactions of new active substances: mibefradil example","display_name":"Drug-drug interactions of new active substances: mibefradil example","publication_year":1999,"publication_date":"1999-10-12","ids":{"openalex":"https://openalex.org/W1978379264","doi":"https://doi.org/10.1007/s002280050673","mag":"1978379264","pmid":"https://pubmed.ncbi.nlm.nih.gov/10541773"},"language":"en","primary_location":{"id":"doi:10.1007/s002280050673","doi":"https://doi.org/10.1007/s002280050673","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s002280050673","pdf_url":null,"source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001926334","display_name":"Krayenb\u00fchl Jc","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. C. Krayenb\u00fchl","raw_affiliation_strings":["Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland","Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland, , , , , , CH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland, , , , , , CH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110397807","display_name":"S. Vo\u017eeh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Vozeh","raw_affiliation_strings":["Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland, , , , , , CH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swiss Intercantonal Office for the Control of Medicines, Berne, Switzerland, , , , , , CH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045822785","display_name":"Mitsuko Kondo-Oestreicher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106256","display_name":"University Hospital of Geneva","ror":"https://ror.org/01m1pv723","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210106256"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"M. Kondo-Oestreicher","raw_affiliation_strings":["Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932; Fax: +41-22-3829940, , , , , , CH","Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932","Fax: +41-22-3829940, , , , , , CH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932; Fax: +41-22-3829940, , , , , , CH","institution_ids":["https://openalex.org/I4210106256"]},{"raw_affiliation_string":"Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932","institution_ids":["https://openalex.org/I4210106256"]},{"raw_affiliation_string":"Fax: +41-22-3829940, , , , , , CH","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019857762","display_name":"Pierre Dayer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106256","display_name":"University Hospital of Geneva","ror":"https://ror.org/01m1pv723","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210106256"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"P. Dayer","raw_affiliation_strings":["Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932; Fax: +41-22-3829940, , , , , , CH","Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932","Fax: +41-22-3829940, , , , , , CH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932; Fax: +41-22-3829940, , , , , , CH","institution_ids":["https://openalex.org/I4210106256"]},{"raw_affiliation_string":"Division of Clinical Pharmacology, University Hospital Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland Tel.: +41-22-3829932","institution_ids":["https://openalex.org/I4210106256"]},{"raw_affiliation_string":"Fax: +41-22-3829940, , , , , , CH","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":null,"fwci":2.1281,"has_fulltext":false,"cited_by_count":90,"citation_normalized_percentile":{"value":0.85110517,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"55","issue":"8","first_page":"559","last_page":"565"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.35350000858306885,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.35350000858306885,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.3359000086784363,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10496","display_name":"Pharmaceutical Practices and Patient Outcomes","score":0.149399995803833,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mibefradil","display_name":"mibefradil","score":0.996999979019165},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9950000047683716},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.902999997138977},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.949999988079071},{"id":"https://openalex.org/keywords/pharmacodynamic-interactions","display_name":"pharmacodynamic interactions","score":0.9959999918937683},{"id":"https://openalex.org/keywords/drug-withdrawal","display_name":"drug withdrawal","score":0.7099999785423279},{"id":"https://openalex.org/keywords/congestive-heart-failure","display_name":"congestive heart failure","score":0.8360000252723694},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.5230000019073486},{"id":"https://openalex.org/keywords/prescribing-information","display_name":"prescribing information","score":0.6679999828338623},{"id":"https://openalex.org/keywords/interaction-prediction","display_name":"interaction prediction","score":0.382999986410141},{"id":"https://openalex.org/keywords/cardiovascular-drugs","display_name":"cardiovascular drugs","score":0.5419999957084656}],"concepts":[{"id":"https://openalex.org/C2778673320","wikidata":"https://www.wikidata.org/wiki/Q6827783","display_name":"Mibefradil","level":4,"score":0.9861227869987488},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6752281785011292},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6409903764724731},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5998491644859314},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5893778204917908},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.5868773460388184},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5080869197845459},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3517524003982544},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.2805039882659912},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.258293479681015},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013557","descriptor_name":"Switzerland","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020748","descriptor_name":"Mibefradil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D020748","descriptor_name":"Mibefradil","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1007/s002280050673","doi":"https://doi.org/10.1007/s002280050673","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s002280050673","pdf_url":null,"source":{"id":"https://openalex.org/S31780008","display_name":"European Journal of Clinical Pharmacology","issn_l":"0031-6970","issn":["0031-6970","1432-1041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:10541773","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10541773","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W28980388","https://openalex.org/W1757924442","https://openalex.org/W1966835639","https://openalex.org/W1987710237","https://openalex.org/W1988552246","https://openalex.org/W1991684478","https://openalex.org/W2009123418","https://openalex.org/W2015399502","https://openalex.org/W2016269688","https://openalex.org/W2021127401","https://openalex.org/W2040869398","https://openalex.org/W2042394561","https://openalex.org/W2050936227","https://openalex.org/W2053798040","https://openalex.org/W2064102714","https://openalex.org/W2076195455","https://openalex.org/W2085927795","https://openalex.org/W2107567093","https://openalex.org/W2161457375","https://openalex.org/W2321430508","https://openalex.org/W2330817322","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2166931842","https://openalex.org/W4244526231","https://openalex.org/W2315748083","https://openalex.org/W4255385226","https://openalex.org/W4240774468","https://openalex.org/W4231281877","https://openalex.org/W2050936227","https://openalex.org/W2105298070","https://openalex.org/W3090072190","https://openalex.org/W2346743634"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}